BR9808529A - Oligopeptìdeo, processos para inibir a ativação de células linfocìticas, para transplantar um órgão de mamìferos doador ou células diferentes das de uma parte de um órgão viável para um recipiente mamìfero, para inibir a produção de uma proteìna de citocina inflamatória, para inibir uma resposta inflamatória em um mamìfero, para modular a atividade de uma enzima contendo heme, e, para retardar o inìcio de uma doença autoimune em um mamìfero em risco de desenvolver referida doença - Google Patents

Oligopeptìdeo, processos para inibir a ativação de células linfocìticas, para transplantar um órgão de mamìferos doador ou células diferentes das de uma parte de um órgão viável para um recipiente mamìfero, para inibir a produção de uma proteìna de citocina inflamatória, para inibir uma resposta inflamatória em um mamìfero, para modular a atividade de uma enzima contendo heme, e, para retardar o inìcio de uma doença autoimune em um mamìfero em risco de desenvolver referida doença

Info

Publication number
BR9808529A
BR9808529A BR9808529-8A BR9808529A BR9808529A BR 9808529 A BR9808529 A BR 9808529A BR 9808529 A BR9808529 A BR 9808529A BR 9808529 A BR9808529 A BR 9808529A
Authority
BR
Brazil
Prior art keywords
inhibit
cells
mammal
activity
organ
Prior art date
Application number
BR9808529-8A
Other languages
English (en)
Other versions
BR9808529B1 (pt
Inventor
Roland Buelow
Gerard Grassy
Bernard Calas
Original Assignee
Sangstat Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/028,083 external-priority patent/US6696545B1/en
Application filed by Sangstat Medical Corp filed Critical Sangstat Medical Corp
Publication of BR9808529A publication Critical patent/BR9808529A/pt
Publication of BR9808529B1 publication Critical patent/BR9808529B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"OLIGOPEPTìDEO, PROCESSOS PARA INIBIR A ATIVAçãO DE CéLULAS LINFOCìTICAS, PARA TRANSPLANTAR UM óRGãO DE MAMìFEROS DOADOR OU CéLULAS DIFERENTES DAS DE UMA PARTE DE UM óRGãO VIáVEL PARA UM RECIPIENTE MAMìFERO, PARA INIBIR A PRODUçãO DE UMA PROTEìNA DE CITOCINA INFLAMATóRIA, PARA INIBIR UMA RESPOSTA INFLAMATóRIA EM UM MAMìFERO, PARA MODULAR A ATIVIDADE DE UMA ENZIMA CONTENDO HEME, E, PARA RETARDAR O INìCIO DE UMA DOENçA AUTOIMUNE EM UM MAMìFERO EM RISCO DE DESENVOLVER REFERIDA DOENçA". Novos oligopeptídeos compreendendo uma seq³ência derivada por um programa de computador são providos para uso na inibição de atividade citotóxica de células linfocíticas, inibindo a produção de citocinas inflamatórias e respostas inflamatórias associadas com as citocinas, inibindo a atividade de enzimas contendo heme e retardando o início de doença autoimune em um mamífero em risco de desenvolver a doença. Por combinação das composições em questão com misturas de células compreendendo células linfocíticas e células que de outra forma ativam as células linfocíticas, a lise das células de marcação pode ser substancialmente inibida. Os oligopeptídeos podem ser unidos a uma ampla variedade de outros grupos ou compostos para variar a atividade das composições em questão. As composições em questão podem ser administradas por qualquer meio conveniente para um hospedeiro para inibir o ataque linfocítico em tecido, particularmente envolvido com transplantes xenogenêicos ou alogeneicos ou para inibir a produção de citocinas inflamatórias e respostas inflamatórias associadas com as mesmas. As composições em questão também podem ser usadas na inibição da atividade de enzimas contendo heme.
BRPI9808529-8A 1997-04-11 1998-04-10 oligopeptìdeo. BR9808529B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83891697A 1997-04-11 1997-04-11
US09/028,083 US6696545B1 (en) 1997-04-11 1998-02-23 Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
PCT/US1998/007231 WO1998046633A1 (en) 1997-04-11 1998-04-10 Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation

Publications (2)

Publication Number Publication Date
BR9808529A true BR9808529A (pt) 2000-10-24
BR9808529B1 BR9808529B1 (pt) 2010-10-05

Family

ID=26703275

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9808529-8A BR9808529B1 (pt) 1997-04-11 1998-04-10 oligopeptìdeo.

Country Status (14)

Country Link
US (1) US7267822B2 (pt)
EP (1) EP0973799B1 (pt)
JP (1) JP4550171B2 (pt)
CN (1) CN1216900C (pt)
AT (1) ATE352556T1 (pt)
AU (2) AU761717B2 (pt)
BR (1) BR9808529B1 (pt)
CA (1) CA2286478A1 (pt)
IL (1) IL132310A0 (pt)
NO (1) NO994898L (pt)
NZ (1) NZ500287A (pt)
PL (1) PL336302A1 (pt)
TR (1) TR199902786T2 (pt)
WO (1) WO1998046633A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773240B1 (fr) 1997-12-30 2002-11-29 Synt Em Procede pour prevoir, identifier et decrire des molecules susceptibles de presenter un comportement recherche, notamment dans le domaine de la pharmacie et molecules obtenues par ce procede
WO2000063350A2 (en) * 1999-04-21 2000-10-26 The University Of Georgia Research Foundation, Inc. Cysteine protease and inhibitors for prevention and treatment of neurocysticerocosis
CA2474056A1 (en) 2002-01-24 2003-07-31 Sangstat Medical Corporation Combination therapy for treatment of hiv infection
WO2003072061A2 (en) * 2002-02-26 2003-09-04 Sangstat Medical Corporation Methods and compositions for treating gastrointestinal toxicity induced by cytoablative therapy
FR2842738B1 (fr) * 2002-07-23 2006-02-10 Negma Lerads Utilisation d'une rheine pour la preparation d'un medicament pour le traitement de l'inflammation chronique, la prevention et le traitement du rejet des transplantations d'organes et de tissus
WO2004045554A2 (en) * 2002-11-15 2004-06-03 Sangstat Medical Corporation Cytomodulating peptides for treating interstitial cystitis
WO2005009457A1 (en) * 2003-05-15 2005-02-03 Sangstat Medical Corporation Rdp58 compositions and methods for inhibiting vascularization of cell populations
WO2005001075A1 (en) * 2003-05-15 2005-01-06 Sangstat Medical Corporation Rdp58 compositions and methods for modulating the activity of osteoclasts and osteoblasts
WO2005053727A2 (en) 2003-11-29 2005-06-16 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
CN104231054A (zh) * 2014-09-01 2014-12-24 王跃建 Il-10多肽抑制剂

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723128A (en) * 1987-01-30 1998-03-03 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic T-cell lymphocyte ("CTL") activity regulation by class I MHC peptides
AU619458B2 (en) 1987-01-30 1992-01-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte inhibition by hla peptides
US5888512A (en) * 1987-01-30 1999-03-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by HLA peptides
US5385888A (en) * 1987-03-20 1995-01-31 The Regents Of The University Of California Class I MHC modulation or surface receptor activity
WO1990010016A1 (en) 1989-03-03 1990-09-07 The Regents Of The University Of California Class i mhc modulation of surface receptor activity
EP1018344A3 (en) * 1991-08-26 2000-09-20 Epimmune, Inc. HLA-restricted hepatitis B virus CTL epitopes
EP0661985B1 (en) 1991-11-08 1999-07-07 The Board Of Trustees Of The Leland Stanford Junior University Peptides capable of binding cd8 molecules on ctl precursors
US5440015A (en) 1992-07-21 1995-08-08 Glycomed Incorporated Selectin peptide medicaments for treating disease
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
AU1093995A (en) * 1993-11-10 1995-05-29 Board Of Trustees Of The Leland Stanford Junior University Surface membrane proteins and their effect on immune response
EP0749488A1 (en) * 1994-03-03 1996-12-27 Genentech, Inc. Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
WO1996022306A1 (en) * 1995-01-16 1996-07-25 Northern Sydney Area Health Service Novel peptide
US6162434A (en) * 1995-05-03 2000-12-19 Sangstat Medical Corporation Cytomodulating peptide for inhibiting lymphocyte activity
US5753625A (en) * 1995-05-12 1998-05-19 Sangstat Medical Corporation Treatment for inhibiting the progression of autoimmune disease
AU1823697A (en) 1996-01-02 1997-07-28 Board Of Trustees Of The Leland Stanford Junior University Interaction of hla proteins with members of the hsp70 family of proteins
US6436903B1 (en) 1996-05-22 2002-08-20 Stanford University (Board Of Trustees Of The Leland Standford Junior University) Immunomodulating compounds comprising d-isomers of amino acids
WO1997044351A1 (en) 1996-05-24 1997-11-27 The Board Of Trustees Of Leland Stanford Junior University Immunomodulating dimers
US6696545B1 (en) * 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation

Also Published As

Publication number Publication date
AU761717B2 (en) 2003-06-05
JP4550171B2 (ja) 2010-09-22
JP2001526641A (ja) 2001-12-18
US20040248810A1 (en) 2004-12-09
US7267822B2 (en) 2007-09-11
IL132310A0 (en) 2001-03-19
AU2003244571A1 (en) 2003-10-02
NO994898L (no) 1999-11-24
CA2286478A1 (en) 1998-10-22
EP0973799B1 (en) 2007-01-24
ATE352556T1 (de) 2007-02-15
CN1216900C (zh) 2005-08-31
NZ500287A (en) 2002-10-25
NO994898D0 (no) 1999-10-08
EP0973799A1 (en) 2000-01-26
WO1998046633A1 (en) 1998-10-22
PL336302A1 (en) 2000-06-19
BR9808529B1 (pt) 2010-10-05
AU6897898A (en) 1998-11-11
TR199902786T2 (xx) 2000-06-21
AU2003244571B2 (en) 2007-07-05
CN1259958A (zh) 2000-07-12

Similar Documents

Publication Publication Date Title
Powis et al. Properties and biological activities of thioredoxins
Levin et al. Regulation of protein synthesis in reticulocyte lysates: phosphorylation of methionyl-tRNAf binding factor by protein kinase activity of translational inhibitor isolated from hemedeficient lysates.
Yamashita et al. Induction of manganese superoxide dismutase in rat cardiac myocytes increases tolerance to hypoxia 24 hours after preconditioning.
Gorrell et al. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes
Czeloth et al. Sphingosine-1-phosphate mediates migration of mature dendritic cells
Stromnes et al. Abrogating Cbl-b in effector CD8+ T cells improves the efficacy of adoptive therapy of leukemia in mice
Dwyer et al. Promoting immune regulation in type 1 diabetes using low-dose interleukin-2
BR9808529A (pt) Oligopeptìdeo, processos para inibir a ativação de células linfocìticas, para transplantar um órgão de mamìferos doador ou células diferentes das de uma parte de um órgão viável para um recipiente mamìfero, para inibir a produção de uma proteìna de citocina inflamatória, para inibir uma resposta inflamatória em um mamìfero, para modular a atividade de uma enzima contendo heme, e, para retardar o inìcio de uma doença autoimune em um mamìfero em risco de desenvolver referida doença
TR199801168T2 (xx) �nterleukin-1 beta d�n��t�r�c� enzim inhibit�rleri.
Czaja Targeting apoptosis in autoimmune hepatitis
Menu et al. Immunoactive products of human placenta: I. An immunoregulatory factor obtained from explant cultures of human placenta inhibits CTL generation and cytotoxic effector activity
Oguro et al. The mode of action of aphidicolin on DNA synthesis in isolated nuclei
DE60017141D1 (de) Replikationskompetente anti-tumor vektoren
Rowland et al. Cardioadaptation induced by cyclic ischemic preconditioning is mediated by translational regulation ofde novoprotein synthesis
PT1003525E (pt) Composicao e metodo para a regulacao da proliferacao e da morte celular
Mimura et al. Binding of an Intrinsic ATPase Inhibitor to the Interface between αand β-Subunits of FiFoATPase upon De-Energization of Mitochondria
Li et al. Signaling on telomerase: a master switch in cell aging and immortalization
DE69903559D1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
Michalek et al. Peroxiredoxin II regulates effector and secondary memory CD8+ T cell responses
Takeuchi et al. The lectin concanavalin A stimulates a protein-tyrosine kinase p72syk in peripheral blood lymphocytes
SHIOTA et al. Cytosolic 20α-hydroxysteroid dehydrogenase activity in spontaneous neoplasms in the dog and cat
DE60043937D1 (de) Eine in vivo "bibliothek-gegen-bibliothek-selektion" von optimierten protein-protein-wechselwirkungen
Chaillou et al. NDUFA4L2–Connecting Metabolic Signals and Mitochondrial Function in Cardiac and Skeletal Muscle
Dünnbier The role of Thioredoxin-interacting protein in T cell receptor signalling
Voskar Present problems of wolf preservation in Czechoslovakia.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/10/2010, OBSERVADAS AS CONDICOES LEGAIS.

B24C Patent annual fee: request for for restoration

Free format text: REFERENTE A 12A ANUIDADE.

B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2606 DE 15-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.